Rest of World (excluding U.S., Europe, Japan)
Knight is actively looking for potential products and companies that fit within its existing business model, but that are in select areas such as Latin America, Israel, Australia, the Middle-East, Sub-Saharan Africa, and the Caribbean. Knight is interested in acquiring an equity position in companies that are in these high growth countries which are non-core geographies. To discuss partnership opportunities, contact us at firstname.lastname@example.org.
On October 21, 2019, Knight announced that it had entered into an agreement to acquire the
controlling interest in Grupo Biotoscana S.A. (GBT), a pan‐Latin American specialty pharmaceutical company. GBT is a biopharmaceutical group that operates in the fast‐growing Latin American region and focuses on rapidly growing market segments such as oncology and onco‐hematology, infectious diseases and other specialty therapeutic areas. GBT is currently present throughout 10 Latin American countries where it operates through four companies, namely, Biotoscana, United Medical, LKM and DOSA. On November 29, 2019, Knight completed the acquisition of 51.2% of GBT. On December 20, 2019, Knight announced that it had submitted to B3 S.A. the authorization request to carry out the Unified Tender Offer to acquire the balance of GBT.
Knight is currently looking for international partners interested in-licensing the rights to the following products:
Neuragen®: Clinically proven to reduce peripheral neuropathic pain quickly and without many of the side effects common with prescription medications
Impavido: For patients with Visceral, Mucosal and Cutaneous Leishmaniasis